These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 17646360)

  • 1. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
    Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
    Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF
    Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
    Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.
    Henning LN; Carpenter S; Stark GV; Serbina NV
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections.
    vor dem Esche U; Huber M; Zgaga-Griesz A; Grunow R; Beyer W; Hahn U; Bessler WG
    Immunobiology; 2011 Jul; 216(7):847-53. PubMed ID: 21397977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S; Little S; Friedlander A; Fritz D; Fellows P
    Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
    Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
    Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
    Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice.
    Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB
    Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of a panel of monoclonal antibodies and polyclonal sera against anthrax toxins resulted in identification of an anti-lethal factor antibody with disease-enhancing characteristics.
    Kulshreshtha P; Tiwari A; Priyanka ; Joon S; Sinha S; Bhatnagar R
    Mol Immunol; 2015 Dec; 68(2 Pt A):185-93. PubMed ID: 26364143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
    Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW
    FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
    Zeng M; Xu Q; Pichichero ME
    Vaccine; 2007 May; 25(18):3588-94. PubMed ID: 17293013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.
    Kobiler D; Gozes Y; Rosenberg H; Marcus D; Reuveny S; Altboum Z
    Infect Immun; 2002 Feb; 70(2):544-60. PubMed ID: 11796581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.
    Mohamed N; Clagett M; Li J; Jones S; Pincus S; D'Alia G; Nardone L; Babin M; Spitalny G; Casey L
    Infect Immun; 2005 Feb; 73(2):795-802. PubMed ID: 15664918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
    Park YS; Lee JH; Hung CF; Wu TC; Kim TW
    Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.
    Pohl MA; Rivera J; Nakouzi A; Chow SK; Casadevall A
    Infect Immun; 2013 Jun; 81(6):1880-8. PubMed ID: 23509144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
    Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG
    Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.